Helix BioPharma Corp. (Helix) is a biopharmaceutical company focused on cancer therapy. Helix is developing products for the treatment and prevention of cancer based on its technologies. The Company�s product development initiatives have focused on its L-DOS47 and Topical Interferon Alpha-2b new drug candidates. As of July 31, 2012, the Company derived its revenue from distribution in Canada from Klean-Prep1, Orthovisc1, Monovisc1, Immunovir1 and Normacol1. The Company has a profitable distribution business in Canada. The products distributed in Canada include Orthovisc and Monovisc, treatments for osteoarthritis of the knee; Klean-Prep and Normacol, gastrointestinal products, and Imunovir, an immune system modulating drug. During the fiscal year ended July 31, 2012 (fiscal 2012), its product revenue derived mainly from the sale in Canada of Klean-Prep, Orthovisc and Monovisc. In August 2013, Helix BioPharma Corp established a Polish subsidiary (Helix Polska).